Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent erysipelas: 47 cases.

S Leclerc1, A Teixeira, E Mahé

  • 1Department of Internal Medicine, Hôpital de la Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie-Paris 6, Paris, France.

Dermatology (Basel, Switzerland)
|December 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study.

ESMO gastrointestinal oncology·2026
Same author

Online food allergen labeling: is it a matter of concern?

European annals of allergy and clinical immunology·2024
Same author

Integrative phylogenetic, phylogeographic and morphological characterisation of the Unio crassus species complex reveals cryptic diversity with important conservation implications.

Molecular phylogenetics and evolution·2024
Same author

Intensity of exercise in people with COPD enrolled in community-based physical activities.

Pulmonology·2023
Same author

The Frailty of the Invincible.

Translational medicine @ UniSa·2021
Same author

Comparison of explicit values clarification method (VCM), implicit VCM and no VCM decision aids for men considering prostate cancer screening: protocol of a randomized trial.

BMC medical informatics and decision making·2020
Same journal

Survey on Difficult to Treat Tinea: A Sub-Saharan Africa Snapshot.

Dermatology (Basel, Switzerland)·2026
Same journal

Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.

Dermatology (Basel, Switzerland)·2026
Same journal

Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study.

Dermatology (Basel, Switzerland)·2026
Same journal

Descriptive Analysis of DRESS Reports from EudraVigilance and DRESS Cases from the RegiSCAR-project.

Dermatology (Basel, Switzerland)·2026
Same journal

The Role of the Vagus Nerve and Its Stimulation in Modulating Inflammatory Skin Diseases and Other Dermatologic Conditions: From Mechanisms to Therapeutics.

Dermatology (Basel, Switzerland)·2026
Same journal

Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors.

Dermatology (Basel, Switzerland)·2026
See all related articles

Recurrent erysipelas (cellulitis) shares risk factors with initial episodes. Antibiotic prophylaxis, particularly for patients with disrupted skin barriers, significantly reduces recurrence rates.

Area of Science:

  • Infectious Diseases
  • Dermatology
  • Epidemiology

Background:

  • Recurrence is a frequent complication of erysipelas (cellulitis).
  • Understanding recurrence patterns is crucial for effective patient management.
  • Identifying risk factors aids in preventing subsequent erysipelas episodes.

Purpose of the Study:

  • To characterize patients experiencing recurrent erysipelas.
  • To identify potential risk factors associated with erysipelas recurrence.
  • To evaluate the efficacy of antibiotic prophylaxis in preventing erysipelas recurrence.

Main Methods:

  • Retrospective analysis of 47 patients hospitalized for erysipelas recurrence (1995-2003).
  • Inclusion of variables such as general condition, regional, and local factors (e.g., cutaneous barrier disruption).

Related Experiment Videos

  • Utilized classification and regression tree methodology for patient characteristic modeling.

    • Main Results:

    • Patients experienced an average of 4.1 recurrences.
    • Cutaneous barrier disruption, primarily intertrigo, was present in 81% of cases.
    • Antibiotic prophylaxis (68% of patients) was administered for a mean of 30.6 months, with 84% and 72% remaining recurrence-free after 1 and 2 years, respectively.

    Conclusions:

    • Erysipelas recurrence shares the same risk factors as initial erysipelas episodes.
    • Oral or parenteral antibiotic prophylaxis demonstrates potential benefit in preventing erysipelas recurrence.
    • Addressing risk factors like cutaneous barrier disruption is essential for managing recurrent erysipelas.